KEAP1/Nrf2 pathway inactivation (through KEAP1 or Nrf2 mutations for example) can be a poor prognostic factor for HCC treatment and help clinicians predict the characteristics of specific cancers. The gene discussed is KEAP1; the disease is cancer.